Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study.
J Autism Dev Disord
; 43(8): 1773-83, 2013 Aug.
Article
em En
| MEDLINE
| ID: mdl-23212807
ABSTRACT
Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients (N = 96; 5-17 years), received risperidone (low-dose 0.125 mg/day [20 to <45 kg], 0.175 mg/day [>45 kg] or high-dose 1.25 mg/day [20 to <45 kg], 1.75 mg/day [>45 kg]) or placebo. Mean baseline (range 27-29) to endpoint change in Aberrant Behavior Checklist-Irritability (primary endpoint) was significantly greater in the high-dose-(-12.4 [6.5]; p < 0.001), but not low-dose (-7.4 [8.1]; p = 0.164) group, versus placebo (-3.5 [10.7]). Clinical Global Impressions-Severity and Children's Yale-Brown Obsessive Compulsive Scale scores improved significantly only in the high-dose group, consistent with ABC-I results. Somnolence, sedation and increased appetite occurred more frequently in high-versus low-dose groups. Overall, increased appetite occurred most frequently.
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
1_ASSA2030
Base de dados:
MEDLINE
Assunto principal:
Antagonistas da Serotonina
/
Transtorno Autístico
/
Risperidona
Tipo de estudo:
Clinical_trials
Limite:
Adolescent
/
Child
/
Child, preschool
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Autism Dev Disord
Ano de publicação:
2013
Tipo de documento:
Article